Custopharm parent agrees to divest steroid drug to resolve US FTC concerns with Hikma deal
MLex Summary: Custopharm’s parent company has agreed to transfer Custopharm’s assets related to the corticosteroid drug triamcinolone acetonide, or TCA, to its Long Grove Pharmaceuticals subsidiary. With the divestiture, the US...To view the full article, register now.
Already a subscriber? Click here to view full article